Volume | 12,927 |
|
|||||
News | - | ||||||
Day High | 2.129 | Low High |
|||||
Day Low | 1.9739 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.04 | 1.9739 | 2.129 | 1.99 | 2.09 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
107 | 12,927 | $ 2.01 | $ 25,934 | - | 1.3601 - 4.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:36:27 | 20 | $ 2.07 | USD |
Aeterna Zentaris Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
13.16M | 4.86M | - | 5.64M | -22.73M | -4.68 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aeterna Zentaris News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.64 | 2.24 | 1.64 | 2.11 | 25,289 | 0.35 | 21.34% |
1 Month | 1.45 | 2.24 | 1.3601 | 1.81 | 11,430 | 0.54 | 37.24% |
3 Months | 2.63 | 2.74 | 1.3601 | 1.97 | 10,060 | -0.64 | -24.33% |
6 Months | 2.78 | 3.21 | 1.3601 | 2.45 | 10,020 | -0.79 | -28.42% |
1 Year | 3.63 | 4.00 | 1.3601 | 2.92 | 12,929 | -1.64 | -45.18% |
3 Years | 0.42 | 5.90 | 0.1645 | 1.29 | 2,456,218 | 1.57 | 373.81% |
5 Years | 3.10 | 5.90 | 0.1645 | 1.18 | 1,874,345 | -1.11 | -35.81% |
Aeterna Zentaris Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |